Absolve & Abscent, launched in Kentucky in 2019 has delivered leading obesity treatment / weight loss results. An innovation from J Craig pharma benefits from a positive patent opinion - worldwide. This is an in-licensing opportunity for pharma or biotech companies to have a stake in the huge and growing obesity market.

1. Absolve &
Abscent

2. REGIONAL / GLOBAL
LICENSING
OPPORTUNITY FROM
J.CRAIG PHARMA

3. Document Confidentiality Statement
The information in this document is confidential to the person to whom it is addressed
and should not be disclosed to any other person. It may not be reproduced in whole, or
in part, nor may any of the information contained therein be disclosed without the prior
consent of the directors of DyoDelta Biosciences (‘the Company’). A recipient may not
solicit, directly or indirectly (whether through an agent or otherwise) the participation of
another institution or person without the prior approval of the directors of the Company.
The contents of this document have not been independently verified and they do not
purport to be comprehensive, or to contain all the information that a prospective partner
may need. No representation, warranty or undertaking, expressed or implied is or will
be made or given and no responsibility or liability is or will be accepted by the Company
or by any of its directors, employees or advisors in relation to the accuracy or
completeness of this document or any other written or oral information made available
in connection with the Company.
Any form of reproduction, dissemination, copying, disclosure, modification, distribution
and or publication of this material is strictly prohibited.

4. Market Drivers and Dynamics

5. Obesity is the new hypertension and looks set to become the next
blockbuster pharma category. Classified by the American Medical
Association (2013) and now the European Commission (2021) as a
chronic disease, obesity is on the cusp of moving into mainstream
primary care.
The obesity market is where the treatment of high blood pressure was in
the mid-to-late 1980's before it transformed into a $30bn market by the
end of 1990’s.

6. • 1 in 5 adults classed as obese in
OECD
• 40% adult obesity prevalence in U.S.
• Estimated 3% drag on annual global
GDP
• Prevalence increased by 150%
between 1976 and 2016 across
OECD
• Developing countries host 115 million
obese adults
• Growth in obesity prevalence in
OCED is slowing but the epidemic is
spreading geographically
#Globesity

7. 40
34
33
32
30
28
28
28
27
26
26
10
9
12
5
4
0 5 10 15 20 25 30 35 40 45
U.S.
Mexico
Hung…
Portu…
Austr…
U.K.
Thail…
Kenya
Korea
%
Snapshot Adult Obesity Rate % in 2016 or latest
year
Obesity rates are growing
fastest in developing
countries but will continue
to increase in OECD and
higher income countries
until at least 2030

8. SHORT TERM
MARKET
DRIVERS
Novo Nordisk ‘Select’ trial data
- Interim data shows significant risk reduction of
obesity co-morbidities e.g. heart attack, strokes
and cardiovascular disease.
Inflection point for social media
- Evidence of virtuous cycle of education, word
of mouth, testimony – turning point for demand.
Diabetes treatment guideline progression
- Cardio-centric goals were incorporated in 2020
and a greater emphasis on weight-centric
goals is anticipated in 2023.

9. SOCIAL MEDIA
ENGAGEMENT %
INCREASE FOR
OBESITY
3
5
10
20
25
50
95
0
10
20
30
40
50
60
70
80
90
100
Apr-18
Aug-18
Dec-18
Apr-19
Aug-19
Dec-19
Apr-20
Aug-20
Dec-20
Apr-21
Aug-21
Dec-21
Launch of Novo
Nordisk ‘Wegovy’
HALO
EFFECT

10. MEDIUM TERM MARKET DRIVERS
• OBESITY IS A DRAIN ON WORLD GDP: APPROX.
3% P/A CURRENTLY
• OBESITY ACCOUNTS FOR APPROX. 8% OF
NATIONAL HEALTH BUDGETS IN OECD
• GROWING ACCEPTANCE THAT GOVERNMENT
BEHAVIOUR CHANGE PLANS HAVE FAILED
• MORE DATA ON PRODUCT SAFETY ESPECIALLY
GLP-1 AGONISTS
• AFFORDABILITY OF PIPELINE TREATMENTS

11. BROAD RANGE
OF HEALTH
BENEFITS &
MARKETS
0
2
4
6
8
10
12
14
16
18
20
Hypertension
Hyperglycaemia
Dislipidaemia
NAFLD
PCOS
Prevention of T2
Diabetes
Kidney Disease
NASH
Cardiovascular
Disease
CV Mortality
HF
% Improvements per weight loss bracket

12. Obesity currently
in North America
Cholesterol
currently
High blood pressure
currently
Obesity with projected short-
term awareness
Prevalence (m) 142 94 116 142
Diagnosed (m) 9 85 97 56
% patients diagnosed rec advice 7 91 79 40
Actual treated (m) 3.9 47 33 31
% treated 40 55 37 55
% treated, controlled n/a 56 70 n/a
Total Prescriptions (m) 10.2 249 636 250
Current Gross Sales ($m) 1.6 2 8.5 n/a
Approx Revenues ($m) assuming $ 350 / per
prescription
3500 87,000 222,800 88,000
(where statins got to)
Torrent of Demand Building

13. 0
10
20
30
40
50
60
2024 2025 2026 2027 2028 2029 2030
7 9
12
18
24
27
31
2
5
10
13
16
20
23
Market
size
c.
$bn
US$ 54 billion market by 2030
US Ex-US

14. OBESITY
LINKED TO
POOREST
When the median household income is below
$45k a year obesity levels were more than 35%,
this drops to 25% when the household income
rises to $65k a year and drops in a linear fashion
further up the income scale.
 Poorer people simply have more to worry
about than what they eat or being
overweight e.g. lack of job opportunities,
quality healthcare access, discrimination.
 Low-income families live disproportionately
in isolated areas, often having to travel
longer distances on foot to get to shops
selling nutritious food.
Source – Nature – Butley et al. 2020

15. 0 10 20 30 40 50
African American
Hispanic
Caucasian
Asian
50
45
41
16
% ADULT OBESE
SOCIO
ECONOMIC
GROUP
OBESITY PREVALANCE BY
SOCIO ECONOMIC GROUP IN
U.S.
Minority racial groups are more likely
to experience multidimensional
poverty than their White
counterparts.*
•The income of Asian American
families often falls markedly above
other minorities.*
• African-Americans (53%) and
Latinos (43%) are more likely to
receive high-cost mortgages than
Caucasians (18%).**
•African American unemployment
rates are typically double that of
Caucasian Americans. **
Source – *Reeves, Rodrigue, Kneebone 2016. **Logan,
2018.

16. MARKET OPPORTUNITY SUMMARY
Globally recognised health epidemic by governments
and WHO
Huge existing market size and exponential growth
expected
Established link to poverty
Obesity rate growing fastest in developing economies

17. Competitor Landscape

18. MODE OF
ACTION
The treatment of obesity is currently limited to seven
FDA-approved medicines. The majority of which target
serotonergic, dopaminergic or noradrenergic signalling
pathways to reduce appetite.
These include Contrave (a combination of bupropion
and topiramate) and Qsymia (a combination of
phentermine and topiramate).
Xenical works differently, blocking the absorption of
fat.
The most popular approach to date is to target
appetite suppressing hormones (incretins), with GLP-1
the most widely studied target. GLP-1 agonists such
as Novo's Saxenda and Wegovy interact with the
hypothalamus to reduce appetite, but also have
glycemic, cardio-protective and anti-inflammatory
benefit.

19. Product
Name
Active
Ingredient
Approved
How it
works
Presentatio
n
Common
Side Effects
Warnings
Adipex Phentermine Adults
Suppresses
Appetite
Pill
Dry Mouth,
Dizziness,
Insomnia
High blood
pressure,
previous
drug abuse,
glaucoma
Contrave
Naltrexone &
Bupropion
Adults
Suppresses
Appetite or
makes you
feel fuller
sooner
Pill
Dizziness,
increased
blood
pressure,
insomnia
High blood
pressure
Alcohol or
Drug
dependence
Belviq Lorcaserin Adults Pill
Qsymia
Phentermine &
Topiramate
Adults
Suppresses
Appetite
Pill
Constipation,
Dizziness,
Insomnia
Glaucoma &
hyperthyroid
-ism, may
lead to birth
defects

20. Product
Name
Active
Ingredient
Approved How it works
Presentatio
n
Common Side
Effects
Warnings
Zonegran Zonisamide Adults
Appetite
Suppressant
Pill
Alopecia,
anxiety,
depression,
diarrhea,
dizziness
History of
depression,
Poor eye
sight. Risk of
renal stone
formation
Alli Orlistat
Adults and
children
above 12
years
Absorbs less
fat from the
food you eat
Pill
Gas, bowel
urgency, flu,
back pain,
headaches
History of
malabsorbtio
n syndrome,
kidney or
pancreatitis.
Wegovy Semaglutide Adults
Appetite
Suppressant
Injection
Bloating, upset
stomach, gas,
nausea,
dizziness
History of
depression,
heart, liver of
kidney
disease
Saxenda liraglutide
Adults and
children
over 12
Appetite
Suppressant
Injection
Nausea,
confusion,
depression,
anxiety
History of
heart, kidney
or liver
diseases and

21. INTRODUCING ABSOLVE & ABSCENT

22. ABSOLVE
TARGET
PROFILE
Target Indication
Obesity & Non-Alcoholic
Steatohepatitis (NASH)
Active Ingredients Phentermine, Naltrexone
Current Distribution
Obesity Clinics, Kentucky, United
States
Adult / Children Adult
Safety
Active ingredients both FDA
approved
Contraindications Pregnancy
Precautions
High blood pressure, glaucoma,
previous drug dependence
Presentation Oral
Dosing 2 times a day

23. ABSOLVE BENEFITS
No pre-caution needed for
patients treated with
depression with SSRI
Patients report increased
energy and metabolism
Affordable and Sustainable
Treatment
Absolve
Features
Active Ingredients
FDA Approved & In
Use for > 50 years
Innovative Dosing
Stops Hunger
Cravings
Well Tolerated – No
Significant Side
Effects
In clinical use - Real
human efficacy data
and testimony

24. ABSCENT
TARGET
PROFILE
Target Indication
Obesity & Non-Alcoholic
Steatohepatitis
Active Ingredients Azelastine, Lidocaine
Distribution
Obesity Clinics, Kentucky, United
States
Adult / Children Adult
Safety
Active ingredients both FDA
Approved
Contraindications Allergy to active ingredients
Precautions Pregnancy
Presentation Nasal Spray
Dosing Up to 3 times a day

25. ABSCENT
FEATURES &
BENEFITS
Purely Topical
Potential Indications for Pregnant Women
& Children
Behaviour Modifier
Approved Active Ingredients
Patent Pending
Acts on the Olfactory Nerve to Make Food
Tasteless
Helps patients stick to good portion sizes –
overeating loses its appeal when food is
tasteless

26. Crossroads Family Medical
Clinic
Campbellsville
Kentucky
Data presented herein from completed
trial
96 Patients monitored
38 Patients using Absolve and Absent
58 Patients using only Absolve

27. 3
5.6
7.4
10.1
13.5
22
0
5
10
15
20
25
Absolve Absolve & Abscent
Treatment Regime
AVERAGE
KG
LOST
Average weight Loss (kg) at 1, 3, & 6 months by Treatment Method
Month
1
3
6

28. 0
2.5
3.7
7.5
8 8.2
0
3.9
6.3
10.7 11
16.9
0
2
4
6
8
10
12
14
16
18
1 2 3 4 5 6
%
Weight
Loss
Month
Average % Weight Loss over 6 Months
Absolve Absolve & Abscent

29. REAL WORLD DATA (AGGREGATED U.S. BASED DATA)
8.2
16.9
6
5
3
4
0
2
4
6
8
10
12
14
16
18
Absolve Absolve &
Abscent
GLP-1
Agonist
Xenical Belviq Contrave
%
Average % weight loss after 6 months

30. COMPETITIVE COST BASE
220
210
25
200
40
220
50 50
200
180
10
180
30
200
40 40
BELVIQ CONTRAVE TOPAMAX XENICAL ZONEGRAN QYSMIA ABSOLVE ABSCENT
Monthly
USD
Monthly End User Price Range (U.S. market based sources)
high price low price

31. OUTSTANDI
NG COST
EFFICACY
35
900
228
300
420
0 200 400 600 800 1000
Absolve &
Abscent
GLP- 1 Agonist
Xenical
Contrave
Belviq
USD
$USD cost per % weight loss to patient

32. Product manufactured in Kentucky, USA by
compounding pharmacies
Cost of Manufacture app $ 3 for months supply of each
product – ABSOLVE & ABSCENT
End User Price $ 45 – 50 for months supply of each
product
PCT Worldwide Patents filed for ABSOLVE and
ABSCENT – March 2023
U.S. Patent Pending for Abscent
ABSOLVE – FDA 505 (b) (2) Approval Eligible
ABSCENT – PreIND, FDA 505 (b) (2) – Application
Camargo Pharmaceuticals, Ohio, USA

33. ABSOLVE &
ABSCENT
 Market leading weight loss efficacy data
 Approved ingredients
 Well tolerated
 Affordable
 Large margin for manufacturer
 Outstanding - cost per % weight loss

34. J CRAIG PHARMA SEEK COMMERCIAL
PARTNERSHIPS. ALL INTERESTED PARTIES
SHOULD CONTACT ADVISORY PARTNER
DYODELTA BIOSCIENCES AT :
ADAM.FLYNN@DYODELTA.COM
DIMITRI.DIMITRIOU@DYODELTA.COM
ABSOLVE & ABSCENT - A NEW CONCEPT
FOR OBESITY & NASH
SEEKING
POTENTIAL
COMMERCIAL
PARTNERS